Stocks of Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) traded higher last session on Wall Street, up 3.32% to $7.77.
As we calculate the median target price by taking the range between a high of $35.00 and a low of $9.00, we find $27.50. Given the previous closing price of $7.52, this indicates a potential upside of 265.69 percent. PHAT stock price is now -23.99% away from the 50-day moving average and -23.36% away from the 200-day moving average. The market capitalization of the company currently stands at $331.55M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Brokers who have rated the stock have averaged $23.83 as their price target over the next twelve months.
With the price target of $16, Jefferies recently initiated with Buy rating for Phathom Pharmaceuticals Inc. (NASDAQ: PHAT)., while ‘Goldman’ rates the stock as ‘Neutral’.
In other news, Henderson Molly, CFO and CBO sold 2,159 shares of the company’s stock on Nov 21. The stock was sold for $20,726 at an average price of $9.60. Upon completion of the transaction, the CFO and CBO now directly owns 43,341 shares in the company, valued at $0.34 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 21, President and Chief Executive Curran Terrie sold 1,526 shares of the business’s stock. A total of $14,650 was realized by selling the stock at an average price of $9.60. This leaves the insider owning 83,720 shares of the company worth $0.65 million. Insiders disposed of 3,703 shares of company stock worth roughly $28772.309999999998 over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PHAT stock. A new stake in Phathom Pharmaceuticals Inc. shares was purchased by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) during the first quarter worth $18,764,000. CANDRIAM S.C.A. invested $871,000 in shares of PHAT during the first quarter. In the first quarter, HRT FINANCIAL LP acquired a new stake in Phathom Pharmaceuticals Inc. valued at approximately $410,000. MILLENNIUM MANAGEMENT LLC acquired a new stake in PHAT for approximately $392,000. CURI WEALTH MANAGEMENT, LLC purchased a new stake in PHAT valued at around $350,000 in the second quarter. In total, there are 154 active investors with 76.00% ownership of the company’s stock.
Monday’s opening bell rang with an opening price of $7.58 for Phathom Pharmaceuticals Inc. (NASDAQ: PHAT). During the past 12 months, Phathom Pharmaceuticals Inc. has had a low of $6.09 and a high of $19.95. The fifty day moving average price for PHAT is $10.22 and a two-hundred day moving average price translates $10.14 for the stock.
The latest earnings results from Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$1.33, missing analysts’ expectations of -$1.03 by -0.3. This compares to -$0.98 EPS in the same period last year. The company reported revenue of $42.53 million for the quarter, compared to $33.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 28.34 percent. For the current quarter, analysts expect PHAT to generate $200k in revenue.
Phathom Pharmaceuticals Inc.(PHAT) Company Profile
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
